Informed Shared Decision making In Multiple Sclerosis immunotherapy (I
Informed Shared Decision making In Multiple Sclerosis immunotherapy (ISDIMS). A randomised controlled trial to investigate the effects of an evidence-based decision aid on decision-making about immunotherapy in multiple sclerosis.
What it found
A paper reports the results; we have not read it yet. See Papers below.
What it measured
Main measures
Primary endpoint are the 'realized role preferences' defined as the difference between autonomy preferences (pre intervention) and performed autonomy (post appointment). A difference as small as possible is defined as the desirable outcome. Secondary endpoints include the number of continued, changed, interrupted, or newly started immunotherapies. Also, analyses of the 'shared decision process' an
Other measures (1)
Not provided at time of registration
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: Patients with multiple sclerosis who consider a new immunotherapy or who are willing to reconsider a decision (no selection of certain disease courses). Exclusion: Patients with a major cognitive deficit and/or who do not agree to data check at health insurance companies are excluded.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Not provided at time of registration
Papers
Loading reviews and guidelines…
History
Started
Jan 2004
Finished
Dec 2005